Woodford Investment Management Ltd adds Gilead Sciences (GILD) to its portfolio

Gilead Sciences (GILD) : Woodford Investment Management Ltd added new position in Gilead Sciences during the most recent quarter end. The investment management firm now holds 486,800 shares of Gilead Sciences which is valued at $37,361,900 , the company said in a statement filed on Nov 14, 2016 with the SEC.Gilead Sciences makes up approximately 1.39% of Woodford Investment Management Ltd’s portfolio.

Other Hedge Funds, Including , Mariner Wealth Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 3,438 additional shares and now holds a total of 51,777 shares of Gilead Sciences which is valued at $3,973,885. Gilead Sciences makes up approx 0.20% of Mariner Wealth Advisors’s portfolio. Gmt Capital Corp added GILD to its portfolio by purchasing 189,800 company shares during the most recent quarter which is valued at $14,774,032. Gilead Sciences makes up approx 0.29% of Gmt Capital Corp’s portfolio.Cibc World Markets boosted its stake in GILD in the latest quarter, The investment management firm added 42,214 additional shares and now holds a total of 174,942 shares of Gilead Sciences which is valued at $12,553,838. Gilead Sciences makes up approx 0.05% of Cibc World Markets’s portfolio.Regal Investment Advisors reduced its stake in GILD by selling 1,229 shares or 3.54% in the most recent quarter. The Hedge Fund company now holds 33,489 shares of GILD which is valued at $2,474,167. Gilead Sciences makes up approx 0.72% of Regal Investment Advisors’s portfolio.Dowling Yahnke boosted its stake in GILD in the latest quarter, The investment management firm added 2,903 additional shares and now holds a total of 50,667 shares of Gilead Sciences which is valued at $3,715,918. Gilead Sciences makes up approx 0.44% of Dowling Yahnke’s portfolio.

Gilead Sciences closed down -0.96 points or -1.27% at $74.62 with 81,94,306 shares getting traded on Monday. Post opening the session at $75.59, the shares hit an intraday low of $74.25 and an intraday high of $75.74 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Gilead Sciences reported $2.75 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Nov 1, 2016. Analyst had a consensus of $2.84. The company had revenue of $7500.00 million for the quarter, compared to analysts expectations of $7440.39 million. The company’s revenue was down -9.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.22 EPS.

Investors should note that on Nov 1, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Dec 13, 2016 as the ex-dividend date and fixed the record date on Dec 15, 2016. The payable date has been fixed on Dec 29, 2016.

Many Wall Street Analysts have commented on Gilead Sciences. Stifel Initiated Gilead Sciences on Nov 14, 2016 to “Buy”, Price Target of the shares are set at $100.Mizuho Initiated Gilead Sciences on Nov 8, 2016 to “Buy”, Price Target of the shares are set at $88.Shares were Reiterated by RBC Capital Mkts on Nov 2, 2016 to “Outperform” and Lowered the Price Target to $ 90 from a previous price target of $95 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Gilead Sciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Gilead Sciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.